Strength of patient cohorts and biobanks for cardiomyopathy research.

Strength of patient cohorts and biobanks for cardiomyopathy research.
Neth Heart J. 2020 Aug;28(Suppl 1):50-56
Authors: de Boer RA, Nijenkamp LLAM, Silljé HHW, Eijgenraam TR, Parbhudayal R, van Driel B, Huurman R, Michels M, Pei J, Harakalova M, van Lint FHM, Jansen M, Baas AF, Asselbergs FW, van Tintelen JP, Brundel BJJM, Dorsch LM, Schuldt M, Kuster DWD, van der Velden J, DOSIS consortium
Abstract
In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.
PMID: 32780332 [PubMed]

Source: Netherlands Heart Journal - July 31, 2020 Category: Cardiology Authors: de Boer RA, Nijenkamp LLAM, Silljé HHW, Eijgenraam TR, Parbhudayal R, van Driel B, Huurman R, Michels M, Pei J, Harakalova M, van Lint FHM, Jansen M, Baas AF, Asselbergs FW, van Tintelen JP, Brundel BJJM, Dorsch LM, Schuldt M, Kuster DWD, van der Velden Tags: Neth Heart J Source Type: research